Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and ...

Oskar Hansson, a professor of neurology at Lund University, will hold the title of Vice President for Neurodegenerative Disease Early Phase Clinical and Imaging Development at the American ...

Hårt kritiserade Millennium skulle införas i Skåne våren 2025. Nu skjuter regionen upp starten av journalsystemet till efter ...

I must admit, the Finnish language isn’t the easiest, and their November weather is every bit as bleak as Stockholm’s. But I’ve had enough of Sweden’s so-called commitment to “fairness.” The notion ...

Nu tar redaktionen julledigt, men passar på att påminna om några artiklar från hösten som du kanske missade. Vi önskar alla ...

– We look for pioneering companies. That's according to Thomas Eldered, chairman of the board of Flerie Invest, who was one of the speakers at Life Science Sweden's Pharma Outsourcing event last week.

Redan från början var regionen fel ute kring Millennium. Det menar Olle Lidbom, som skrivit boken om den skandalomsusade Skolplattformen. Han får medhåll av it-professorn Johan Magnusson som kallar ...

Ultimovacs is developing the cancer vaccine UV1, which aims to enhance and improve the effect of immunotherapy in various forms of cancer. Zelluna is developing immunotherapies against solid tumors.

Enligt ett pressmeddelande avgår Hans Wigzell på egen begäran, och styrelsen inleder omedelbart arbetet för att hitta en ny ordförande. Någon orsak anges inte, men beskedet kommer bara en dryg vecka ...

American Merck & Co, known in Europe as MSD, has discontinued the development of vibostolimab and favezelimab, two experimental cancer drugs, after their failure in several trials, according to a ...

The new factory, including a warehouse, will cover 40,000 square meters. Construction has already begun, and the facility is expected to be completed in 2027, according to a press release. – We are ...

The announcement came after a review that has been ongoing within the European Medicines Agency (EMA) since October last year, and means that its Committee for Medicinal Products for Human Use (CHMP) ...